Glycemic Control in Diabetic Dialysis Patients and the Burnt-Out Diabetes Phenomenon

被引:43
|
作者
Park, Jongha [1 ,2 ]
Lertdumrongluk, Paungpaga [1 ]
Molnar, Miklos Z. [1 ,3 ]
Kovesdy, Csaba P. [4 ,5 ]
Kalantar-Zadeh, Kamyar [1 ,6 ,7 ]
机构
[1] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Harold Simmons Ctr Kidney Dis Res & Epidemiol, Torrance, CA 90509 USA
[2] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Div Nephrol, Ulsan 680749, South Korea
[3] Semmelweis Univ, Inst Pathophysiol, H-1085 Budapest, Hungary
[4] Univ Virginia, Div Nephrol, Charlottesville, VA USA
[5] Salem VA Med Ctr, Div Nephrol, Salem, VA USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA
关键词
Diabetes mellitus; Chronic kidney disease; Hemoglobin A1c; Glycemic control; Maintenance dialysis; Burnt-out diabetes; Diabetic dialysis; HEMODIALYSIS-PATIENTS; GLYCATED ALBUMIN; INSULIN-RESISTANCE; AMINO-ACIDS; GLUCOSE; HEMOGLOBIN; SURVIVAL; OUTCOMES; DISEASE; IMPACT;
D O I
10.1007/s11892-012-0286-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) is the most common cause of end-stage kidney disease and a major risk of morbidity and mortality. It is not clear whether medical management of DM has any significant beneficial effect on clinical outcomes at the end-stage of diabetic nephropathy with full-blown micro- and macro-angiopathic complications. Both loss of kidney function and dialysis treatment interfere with glucose homeostasis and confound glycemic control. Given the unique nature of uremic milieu and dialysis therapy related alterations, there have been some debates about reliance on the conventional measures of glycemic control, in particular the clinical relevance of hemoglobin A1c and its recommended target range of < 7 % in diabetic dialysis patients. Moreover, a so-called burnt-out diabetes phenomenon has been described, in that many diabetic dialysis patients experience frequent hypoglycemic episodes prompting cessation of their anti-diabetic therapies transiently or even permanently. By reviewing the recent literature we argue that the use of A1c for management of diabetic dialysis patients should be encouraged if appropriate target ranges specific for these patients (e.g. 6 to 8 %) are used. We also argue that "burnt-out diabetes" is a true biologic phenomenon and highly prevalent in dialysis patients with established history and end-stage diabetic nephropathy and explore the role of protein-energy wasting to this end. Similarly, the J- or U-shaped associations between A1c or blood glucose concentrations and mortality are likely biologically plausible phenomena that should be taken into consideration in the management of diabetic dialysis patients to avoid hypoglycemia and its fatal consequences in diabetic dialysis patients.
引用
收藏
页码:432 / 439
页数:8
相关论文
共 50 条
  • [31] Association of glycemic control with hypertension in patients with diabetes: a population-based longitudinal study
    Chen, Shengliang
    Zhu, Yi
    Jin, Sihui
    Zhao, Dongbao
    Guo, Jianwei
    Chen, Lijin
    Huang, Yixiang
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01):
  • [32] Effect of anti-diabetic drugs in dialysis patients with diabetes: a nationwide retrospective cohort study
    Ou, Shih-Hsiang
    Chen, Hsin-Yu
    Fang, Nai-Wen
    Yin, Chun-Hao
    Chen, Chien-Liang
    Chen, Jin-Shuen
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [33] Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus
    Karlin, Nina J.
    Mangold, Aaron R.
    Amin, Shailja B.
    Kosiorek, Heidi E.
    Buras, Matthew R.
    Verona, Patricia M.
    Cooks, Curtiss B.
    FUTURE SCIENCE OA, 2019, 5 (03):
  • [34] Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study
    Abe, Masanori
    Hamano, Takayuki
    Hoshino, Junichi
    Wada, Atsushi
    Nakai, Shigeru
    Masakane, Ikuto
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [35] Glycated albumin may be a choice, but not an alternative marker of glycated hemoglobin for glycemic control assessment in diabetic patients undergoing maintenance hemodialysis
    Chen Feng-kun
    Sun Xue-feng
    Zhang Dong
    Cui Shao-yuan
    Chen Xiang-mei
    Wei Ri-bao
    Lu Ju-ming
    Li Ji-jun
    Liu Wen-hu
    Zhang Dong-liang
    Zhang Zhi-min
    CHINESE MEDICAL JOURNAL, 2013, 126 (17) : 3295 - 3300
  • [36] Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
    Ito, Hiroyuki
    Mifune, Mizuo
    Matsuyama, Eriko
    Furusho, Masahide
    Omoto, Takashi
    Shinozaki, Masahiro
    Nishio, Shinya
    Antoku, Shinichi
    Abe, Mariko
    Togane, Michiko
    Koga, Shoji
    Sanaka, Tsutmou
    DIABETES THERAPY, 2013, 4 (02) : 321 - 329
  • [37] Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
    Hiroyuki Ito
    Mizuo Mifune
    Eriko Matsuyama
    Masahide Furusho
    Takashi Omoto
    Masahiro Shinozaki
    Shinya Nishio
    Shinichi Antoku
    Mariko Abe
    Michiko Togane
    Shoji Koga
    Tsutomu Sanaka
    Diabetes Therapy, 2013, 4 : 321 - 329
  • [38] Glycemic control in diabetic CKD patients: Where do we stand?
    Kovesdy, Csaba P.
    Sharma, Kumar
    Kalantar-Zadeh, Kamyar
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 52 (04) : 766 - 777
  • [39] Indicators of glycemic control in patients with gestational diabetes mellitus and pregnant women with diabetes mellitus
    Hashimoto, Kunihiko
    Koga, Masafumi
    WORLD JOURNAL OF DIABETES, 2015, 6 (08) : 1045 - 1056
  • [40] The association between long-term glycemic control and all-cause mortality is different among older versus younger patients with diabetes mellitus and maintenance hemodialysis treatment
    Afghahi, Hanri
    Nasic, Salmir
    Rydell, Helena
    Svensson, Johan
    Peters, Bjorn
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 191